Renaissance Technologies LLC Has $32,000 Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Renaissance Technologies LLC reduced its stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) by 85.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,600 shares of the company’s stock after selling 63,400 shares during the quarter. Renaissance Technologies LLC’s holdings in TScan Therapeutics were worth $32,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TCRX. abrdn plc increased its position in shares of TScan Therapeutics by 137.8% during the 4th quarter. abrdn plc now owns 883,704 shares of the company’s stock worth $2,686,000 after purchasing an additional 512,049 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of TScan Therapeutics by 94.4% during the third quarter. JPMorgan Chase & Co. now owns 31,805 shares of the company’s stock worth $158,000 after buying an additional 15,441 shares in the last quarter. Barclays PLC raised its stake in shares of TScan Therapeutics by 341.1% in the third quarter. Barclays PLC now owns 58,067 shares of the company’s stock valued at $289,000 after acquiring an additional 44,903 shares during the last quarter. Prudential Financial Inc. acquired a new position in shares of TScan Therapeutics in the 4th quarter worth approximately $32,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in TScan Therapeutics during the 4th quarter worth approximately $32,000. 82.83% of the stock is owned by institutional investors.

TScan Therapeutics Stock Performance

TScan Therapeutics stock opened at $1.38 on Friday. TScan Therapeutics, Inc. has a 1 year low of $1.02 and a 1 year high of $9.69. The company’s 50-day moving average is $1.51 and its two-hundred day moving average is $2.75. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The company has a market cap of $77.81 million, a PE ratio of -1.30 and a beta of 1.06.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The firm had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.62 million. Equities analysts anticipate that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Needham & Company LLC reissued a “buy” rating and issued a $9.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, April 8th. Morgan Stanley restated an “overweight” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a research report on Friday, March 14th. Wedbush reiterated an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a research report on Tuesday. Barclays decreased their price target on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. Finally, HC Wainwright reduced their price objective on TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $8.50.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.